Suchergebnisse - "Popat, Rakesh"

PubPharm (143)

1

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

2

Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma : Final analysis of the DREAMM-2 trial

enthalten in: Cancer | 2023

von Nooka, A. | Cohen, A. | Lee, H. | +21

3

Infections following bispecific antibodies in myeloma : a systematic review and meta-analysis

enthalten in: Blood advances | 2023

von Reynolds, G. | Cliff, E. | Mohyuddin, G. | +6

4

Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma

enthalten in: The Lancet. Haematology | 2023

von Popat, R. | Chavda, S.

CommentOn: Lancet Haematol. 2023 Oct;10(10):e825-e837. - PMID 37708911

5

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2023

von Richardson, P. | Trudel, S. | Popat, R. | +60

6

Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma

enthalten in: British journal of haematology | 2023

von Correia, N. | Dowling, E. | Popat, R. | +5

7

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

enthalten in: Journal of the advanced practitioner in oncology | 2023

von Popat, R. | Lonial, S. | Voorhees, P. | +12

8

Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment : a single center experience

enthalten in: Leukemia & lymphoma | 2023

von Nesr, G. | Shah, R. | Kyriakou, C. | +18

9

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2023

von San-Miguel, J. | Dhakal, B. | Yong, K. | +40

10

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

enthalten in: Journal for immunotherapy of cancer | 2023

von Lee, L. | Lim, W. | Galas-Filipowicz, D. | +25

ErratumIn: J Immunother Cancer. 2023 Jul;11(7):. - PMID 37433719

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[15]